Comments

Regulus Therapeutics Stock Guidance

RGLSNASDAQ
Logo brought to you by Benzinga Data
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$7.98
4.61136.80%
At close: -
$7.90
-0.08-1.00%
After Hours: 6:29 PM EDT
Why is it moving?
Regulus Therapeutics shares are trading higher after the company announced it entered into an agreement to be acquired by Novartis AG for $7 in cash per share.
Regulus Therapeutics (RGLS) announced today it will be merged with Novartis (NVS) for $800.0M paid in cash
Regulus Therapeutics (RGLS) ForecastNewsEarningsRegulus Therapeutics (RGLS) Options

Guidance

DividendsAnalyst RatingsInsider TradesShort Interest

Regulus Therapeutics Stock Guidance | NASDAQ:RGLS | Benzinga

Regulus Therapeutics issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.

Get Alert
Regulus Therapeutics Inc (RGLS) does not provide guidance data

FAQ

Q

What is the most recent guidance for Regulus Therapeutics (RGLS)?

A

There have been no specific sales or earnings guidance reported for Regulus Therapeutics in recent months.

Browse guidance and forecast on all stocks.

People Also Watch

Connect With Us

instagramlinkedinyoutube

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2025 Benzinga | All Rights Reserved